Can You Test for Perimenopause? Diagnosis & Hormone Testing

Why Perimenopause Is Hard to Confirm With One Test

Perimenopause is a transition, not a threshold. Ovarian follicle output becomes erratic years before the final menstrual period, causing estrogen and progesterone to swing widely within a single cycle and between cycles. A blood test taken on day 3 of one cycle may look normal; the same panel two months later may show strikingly elevated FSH.

The STRAW+10 criteria, published in the journal Menopause and endorsed by major reproductive endocrinology societies, define perimenopause by cycle irregularity rather than by hormone levels alone. Early perimenopause (Stage -2) begins when cycles vary by 7 or more days from the usual pattern. Late perimenopause (Stage -1) is defined by at least two consecutive cycles separated by 60 or more days [1].

Because those cycle patterns take months to observe, a single office visit with one blood draw captures only a snapshot of a rapidly shifting system.

The Role of Symptoms in Diagnosis

Symptoms carry real diagnostic weight. Vasomotor symptoms (hot flashes and night sweats), sleep disruption, vaginal dryness, mood changes, and cognitive fog are all reported at higher rates during the menopausal transition than at other reproductive life stages [2]. The Study of Women's Health Across the Nation (SWAN), a multiethnic longitudinal cohort that followed 3,302 women from 1996 onward, documented that 35 to 46 percent of women reported frequent hot flashes during the late transition, compared with 13 to 19 percent in pre-menopausal women of similar age [3].

A clinician who hears that a 48-year-old woman has had two cycles more than 60 days apart and has been waking three times a night drenched in sweat has a working diagnosis of late perimenopause before any lab result comes back.

When Labs Are Ordered Anyway

Testing becomes more useful in specific situations: women under 45 where premature ovarian insufficiency (POI) must be ruled out, women who have had a hysterectomy (no cycle data available), women on hormonal contraception masking cycle changes, and women whose primary care physicians want to exclude thyroid disease, anemia, or other conditions that mimic menopausal symptoms.

FSH: The Most Commonly Ordered Test

FSH is the pituitary hormone that signals ovarian follicles to develop. As ovarian reserve declines, the pituitary compensates by secreting more FSH. Elevated FSH is therefore an indirect marker of reduced ovarian response.

What FSH Values Mean

A serum FSH above 25 IU/L on two separate measurements taken at least four weeks apart is the value most guidelines use to support a perimenopause or menopause diagnosis in symptomatic women [4]. A single reading above 40 IU/L, combined with 12 months of amenorrhea, meets the clinical definition of menopause.

The problem is variability. During early perimenopause, FSH may be elevated in one cycle and entirely normal in the next, because a large follicle can still produce enough estrogen to suppress pituitary output temporarily. The North American Menopause Society (NAMS) states explicitly: "A single FSH measurement is not sufficient to confirm perimenopause or menopause in women who are still having menstrual periods" [4].

FSH and Hormonal Contraception

Women taking combined oral contraceptives (COCs) or progestin-only pills will have artificially suppressed FSH. Testing on-pill is generally unreliable. If cycle-pattern data are needed and the patient is willing, a brief contraception pause of at least 4 to 6 weeks before repeat testing is sometimes recommended, though this must be balanced against the individual's contraceptive needs.

Estradiol: Useful Context, Poor Solo Diagnostic Tool

Estradiol (E2) measures the main circulating estrogen. During perimenopause, estradiol does not simply decline in a linear way. Levels frequently spike above premenopausal norms before ultimately falling, which is why some perimenopausal women experience new or worsening breast tenderness, heavy bleeding, or mood lability alongside the classic low-estrogen symptoms.

Interpreting Estradiol Results

A serum estradiol below 30 pg/mL is consistent with late perimenopause or menopause, but this value has limited predictive power when taken out of context. In the SWAN hormone substudy, within-woman variability in estradiol across 10 annual visits was so wide that a single measurement explained only 17 percent of the variance in vasomotor symptom reporting [3].

Estradiol is still worth measuring when:

• Symptoms suggest hypoestrogenism (vaginal atrophy, bone-pain concern, premature symptoms in a younger woman)
• A clinician is establishing a pre-treatment baseline before starting hormone therapy
• Serial measurements over several months are used to track the trajectory of decline

Pairing FSH and Estradiol

Many clinicians order both simultaneously. A pattern of high FSH plus low estradiol (FSH above 25 IU/L, E2 below 30 pg/mL) is the clearest hormonal signal of ovarian insufficiency. High FSH with normal or elevated E2 is common in early perimenopause and reflects the pituitary working harder to recruit remaining follicles.

Anti-Müllerian Hormone (AMH): The Ovarian Reserve Marker

AMH is secreted by small antral and pre-antral follicles and remains relatively stable across the menstrual cycle, which makes it technically easier to interpret than FSH or estradiol. AMH declines gradually over the reproductive years and reaches nearly undetectable levels in the years just before the final menstrual period.

AMH as a Perimenopause Predictor

A 2017 analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM), using data from the SWAN study (N=1,537 women followed over 9 years), found that AMH measured at baseline predicted time to final menstrual period more accurately than FSH or inhibin B, with a low AMH (below 0.10 ng/mL) associated with final menstrual period within 1 to 3 years [5].

AMH testing is not yet a universal first-line recommendation in routine perimenopause assessment. Current NAMS and Endocrine Society guidelines position AMH primarily as a research and fertility-counseling tool. Its main clinical value in the perimenopause context is in women under 40 being evaluated for POI, or in women where timing of the final period is clinically important (for example, deciding when to transition off contraception).

AMH Reference Ranges by Age

AMH declines predictably with age. Approximate median values from population studies are:

| Age (years) | Median AMH (ng/mL) | |-------------|-------------------| | 25 to 30 | 3.0 to 4.5 | | 35 to 40 | 1.0 to 2.0 | | 42 to 45 | 0.3 to 0.7 | | 47 to 50 | 0.1 to 0.2 | | Post-menopause | <0.1 |

Values below the 10th percentile for age raise concern for accelerated ovarian aging.

The STRAW+10 Staging System: The Clinical Standard

The Stages of Reproductive Aging Workshop (STRAW) criteria, last updated in 2011 and published in Climacteric and Menopause, provide the most widely accepted framework for staging reproductive aging. STRAW+10 divides the female reproductive life span into seven stages, from Stage -5 (reproductive peak) through Stage +2 (late post-menopause) [1].

STRAW+10 Perimenopause Stages in Brief

Stage -2 (Early Menopausal Transition): Cycle length begins to vary by 7 or more days from the woman's usual pattern. FSH may be elevated but is not required for staging. Vasomotor symptoms may begin.

Stage -1 (Late Menopausal Transition): At least two consecutive cycles are separated by 60 or more days (i.e., the woman skips at least one cycle). Elevated FSH and low AMH are expected. Vasomotor symptoms are common and often intense. This stage ends with the final menstrual period (FMP).

Stage +1a (Early Post-Menopause): The first 12 months after FMP. Retrospectively confirmed once 12 months of amenorrhea are complete.

The Endocrine Society's 2015 clinical practice guideline on menopause states: "The menopausal transition is defined primarily by menstrual cycle characteristics, not by hormone levels, because no single hormonal measurement reliably distinguishes the transition from normal menstrual variability" [6].

Why STRAW+10 Matters for Testing Decisions

Knowing a patient's STRAW stage informs which tests add value. In Stage -2, FSH and AMH can help quantify ovarian reserve but rarely change clinical management in a woman with classic symptoms. In Stage -1, FSH is more reliably elevated and an elevated reading (25 IU/L on two draws) is clinically meaningful. In any stage, TSH and a basic metabolic panel should be obtained to rule out thyroid dysfunction, which shares significant symptom overlap with perimenopause.

Tests That Rule Out Other Conditions

Before attributing symptoms to perimenopause, clinicians typically screen for conditions that produce overlapping complaints.

Thyroid Function Testing

Hypothyroidism and hyperthyroidism both cause menstrual irregularity, mood changes, fatigue, and heat or cold intolerance. The American Thyroid Association recommends TSH screening in all women over 50, and earlier screening in symptomatic women [7]. A sensitive TSH (normal range approximately 0.4 to 4.0 mIU/L) is almost always ordered alongside FSH in the initial perimenopause workup. Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) affects approximately 10 percent of women over 45 and can mimic or coexist with perimenopausal symptoms.

Prolactin

Elevated prolactin causes amenorrhea and can be mistaken for early menopause. A serum prolactin should be checked in any woman under 45 presenting with irregular or absent cycles, and in older women whose clinical picture is atypical.

Complete Blood Count and Iron Studies

Heavy or irregular perimenopausal bleeding is a direct cause of iron-deficiency anemia. Fatigue, palpitations, and cognitive slowing attributed to menopause may partly reflect anemia. A CBC with ferritin is a low-cost, high-yield add-on.

Fasting Glucose and Lipid Panel

Estrogen decline during the menopausal transition accelerates atherogenic lipid changes and modestly increases insulin resistance. The American Heart Association notes that cardiovascular risk rises more steeply in women after menopause than in men of equivalent age [8]. Baseline lipid and glucose data gathered during the perimenopause evaluation serve as an anchor for long-term cardiovascular risk management.

Saliva and Urine Hormone Tests: What the Evidence Says

Direct-to-consumer saliva and dried urine hormone panels (often marketed as "DUTCH tests") are popular but not recommended by major medical societies for diagnosing perimenopause. The Endocrine Society's position statement notes that salivary hormone measurements have not been validated for clinical decision-making in the context of perimenopause or menopause, and that reference ranges for saliva-based estradiol vary substantially between laboratories [9].

Salivary cortisol at specific time points has been validated for adrenal disorders, but a broad saliva hormone panel sold as a perimenopause screen does not meet evidence standards.

Premature Ovarian Insufficiency: When to Test Urgently

Premature ovarian insufficiency (POI), defined as loss of normal ovarian function before age 40, affects approximately 1 in 100 women [10]. POI is not simply early menopause; it is associated with higher long-term risks of osteoporosis, cardiovascular disease, and neurological changes compared with natural menopause at the typical age. Women under 40 with irregular or absent periods must be evaluated promptly.

POI Diagnostic Criteria

POI requires:

• Age under 40
• At least 4 months of irregular or absent menstrual periods
• Two FSH measurements above 25 IU/L taken at least four weeks apart [10]

Once POI is confirmed, workup should include karyotype analysis (to exclude Turner syndrome mosaicism), testing for FMR1 premutation (associated with Fragile X), and autoimmune antibody panels (thyroid peroxidase antibodies, 21-hydroxylase antibodies). The European Society of Human Reproduction and Embryology (ESHRE) published specific POI guidelines in 2016 that cover this diagnostic pathway in full [10].

How to Get Tested: Practical Steps

At a Primary Care or OB-GYN Visit

A standard first-line perimenopause hormone panel typically includes: serum FSH, serum estradiol (drawn on cycle day 2 to 5 if cycles are still regular), TSH, prolactin, CBC, ferritin, fasting lipid panel, and fasting glucose. This panel costs between $150 and $400 out-of-pocket depending on laboratory and geographic market; most is covered under preventive care provisions when ordered by a physician for symptomatic evaluation.

Timing Matters

If cycles are still somewhat regular, drawing FSH and estradiol on days 2 to 5 of the menstrual cycle provides the most interpretable results. In women with very irregular cycles or prolonged amenorrhea, any day is acceptable. Repeat FSH at least four weeks after the first draw if the result is borderline.

Telehealth Perimenopause Evaluation

Many telehealth platforms, including HealthRX, now offer complete perimenopause hormone panels with physician review. A digital intake collects symptom history, cycle pattern data, and STRAW-stage relevant information before any blood is drawn, so the lab results are interpreted in clinical context rather than in isolation.

Interpreting Results With Your Clinician

A result comes back. Now what?

FSH of 32 IU/L in a 49-year-old woman who has missed two cycles and is having nightly hot flashes confirms what the history already suggested: late perimenopause. Treatment decisions can proceed.

FSH of 14 IU/L in the same woman with the same symptoms does not rule out perimenopause. It means the test was drawn during a cycle with adequate follicular activity. The diagnosis remains clinical.

FSH of 48 IU/L in a 36-year-old woman with two months of cycle irregularity is a flag for POI and requires a repeat draw, a full autoimmune and genetic workup, and a referral to a reproductive endocrinologist.

No single number replaces the clinical conversation. The NAMS 2023 Position Statement on hormone therapy specifies that "menopausal status should be determined by clinical criteria, with laboratory testing used to clarify ambiguous presentations or to evaluate for underlying pathology" [4].